Michael Yangming Xiao is an associate and a registered foreign lawyer in the Hong Kong office. His practice focuses on anti-bribery and anti-corruption investigations, internal compliance investigations, and compliance risk management. Michael also has experience in international commercial arbitration.
Prior to joining the firm, Michael was a dispute resolution associate at a leading international law firm, where he assisted in a variety of multi-jurisdictional investigations and international commercial arbitrations in New York, London, and Hong Kong.
- Represented a Fortune 500 biotechnology company in conducting internal investigations into potential bribery and revenue recognition issues raised by a whistleblower in China, and assisted the company in conducting proactive risk assessment and compliance control enhancements to mitigate future bribery risks.
- Represented leading global hearing care solutions provider in investigating a whistleblower complaint regarding alleged fraud, embezzlement, bribery and corrupt practices involving internal employees and external distributors.
- Assisted a U.S.-based company focused on analytical instruments, software, services and laboratory consumables in conducting a proactive compliance risk assessment of the company’s operations in China.
- Represented a U.S.-headquartered company with manufacturing operations in China to conduct internal investigations regarding procurement fraud, conflict of interest and embezzlement.
- Assists leading global asset management companies and private equity firms in developing and implementing compliance programs for portfolio companies, including preparing bilingual compliance-related policies and procedures, and conducting anti-corruption, anti-money laundering and trade compliance trainings in both Mandarin and English.
- Assisted the Special Committee of the Board of Directors of an Asia-based biopharmaceutical company to investigate alleged trade secrets misappropriation by company personnel.
- Advised leading international pharmacy and wellbeing enterprise in conducting anti-corruption compliance assessment and post-investment compliance program implementation in connection with a key joint-venture program in China.
- Conducted internal investigations related to anti-bribery, anti-corruption, and embezzlement for Fortune 100 multinational life sciences companies
- Advised one of the world’s largest hotel companies, on a proactive internal investigation undertaken by our client linked to its operations in China
- Represented a prominent U.S.-based manufacturer of medicine and vaccines for pets and livestock in connection with an anti-corruption internal investigation regarding questionable marketing and promotional expenses, and a whistleblower complaint relating to potential violations of the Foreign Corrupt Practices Act at a manufacturing facility in China and third-party misconduct.
- Advised multiple international investment banking, asset management and private equity firms on anti-corruption, anti-money laundering and trade compliance due diligence for investments in Asia
Transactions completed prior to joining Ropes & Gray:
- Advised on anti-fraud and anti-money laundering compliance with respect to an international money services business with agent locations in more than 200 countries
- Advised a German pharmaceutical company in its internal investigation regarding potential non-compliant practices in Vietnam
- Represented a US pharmaceutical company in a multi-year Foreign Corrupt Practices Act investigation led by the US Department of Justice and the US Securities and Exchange Commission, as well as in related internal investigations
- Represented an African state entity in an ICC arbitration against a Japanese construction company arising from a major infrastructure project
- Co-author, “Bid rigging: For multinationals, more than just a local law violation,” Westlaw Journal Government Contract (October 8, 2018)
- Co-Author, “An In-Depth Examination of China’s New Cybersecurity Law Part I: Who Must Comply,” Lexology (July 7, 2017)
- Author, “Deferred/Non Prosecution Agreements: Effective Tools to Combat Corporate Crime,” Cornell Journal of Law and Public Policy Vol. 23 No. 1